Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Sounds Somewhat Muted Drug Pricing Alarm

Executive Summary

Pharma CEOs expect the US pricing situation will remain stable in the near-term but accept drug prices will continue to face pressure and agree that the future remains uncertain. Subsiding rhetoric after elections may bring some relief.

You may also be interested in...



From Pharma Insider To Payer: Witty To Lead United's Optum

Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.

Calif. Prop 61 Raises Industry Concerns Over Ripple Effect

Industry executives are speaking out against the measure that would require California state agencies to pay no more than the US Department of Veterans Affairs pay for drugs.

Pfizer’s Read Criticizes Rebates Amid Changing Market Dynamics

Pfizer CEO Ian Read suggested it might be time for a new solution that would allow the pharma industry to moderate pricing based on volume without relying on rebates, criticizing a practice he said has become “less helpful” in getting cost effective solutions to patients.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC097609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel